These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 9545022)
41. Exogenous glucagon-like peptide-1 reduces body weight and cholecystokinin-8 enhances this reduction in diet-induced obese male rats. Mhalhal TR; Washington MC; Newman K; Heath JC; Sayegh AI Physiol Behav; 2017 Oct; 179():191-199. PubMed ID: 28647503 [TBL] [Abstract][Full Text] [Related]
42. Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats. Schick RR; Zimmermann JP; vorm Walde T; Schusdziarra V Am J Physiol Regul Integr Comp Physiol; 2003 Jun; 284(6):R1427-35. PubMed ID: 12776726 [TBL] [Abstract][Full Text] [Related]
43. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Näslund E; Gutniak M; Skogar S; Rössner S; Hellström PM Am J Clin Nutr; 1998 Sep; 68(3):525-30. PubMed ID: 9734726 [TBL] [Abstract][Full Text] [Related]
44. Dual glucagon recognition by pancreatic beta-cells via glucagon and glucagon-like peptide 1 receptors. Moens K; Flamez D; Van Schravendijk C; Ling Z; Pipeleers D; Schuit F Diabetes; 1998 Jan; 47(1):66-72. PubMed ID: 9421376 [TBL] [Abstract][Full Text] [Related]
45. Glucagon-like peptide-1(7-36)amide: characterization of the domain responsible for binding to its receptor on rat insulinoma RINm5F cells. Gallwitz B; Schmidt WE; Conlon JM; Creutzfeldt W J Mol Endocrinol; 1990 Aug; 5(1):33-9. PubMed ID: 2168708 [TBL] [Abstract][Full Text] [Related]
46. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys. Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313 [TBL] [Abstract][Full Text] [Related]
47. Combined gastrin releasing peptide-29 and glucagon like peptide-1 reduce body weight more than each individual peptide in diet-induced obese male rats. Mhalhal TR; Washington MC; Newman KD; Heath JC; Sayegh AI Neuropeptides; 2018 Feb; 67():71-78. PubMed ID: 29180139 [TBL] [Abstract][Full Text] [Related]
48. Altered glucose dependence of glucagon-like peptide I(7-36)-induced insulin secretion from the Zucker (fa/fa) rat pancreas. Jia X; Elliott R; Kwok YN; Pederson RA; McIntosh CH Diabetes; 1995 May; 44(5):495-500. PubMed ID: 7729605 [TBL] [Abstract][Full Text] [Related]
49. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Bucinskaite V; Tolessa T; Pedersen J; Rydqvist B; Zerihun L; Holst JJ; Hellström PM Neurogastroenterol Motil; 2009 Sep; 21(9):978-e78. PubMed ID: 19453518 [TBL] [Abstract][Full Text] [Related]
50. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Baggio LL; Huang Q; Brown TJ; Drucker DJ Diabetes; 2004 Sep; 53(9):2492-500. PubMed ID: 15331566 [TBL] [Abstract][Full Text] [Related]
51. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Sudre B; Broqua P; White RB; Ashworth D; Evans DM; Haigh R; Junien JL; Aubert ML Diabetes; 2002 May; 51(5):1461-9. PubMed ID: 11978643 [TBL] [Abstract][Full Text] [Related]
52. Glucagon-like peptide-1 (7-36) amide: a central regulator of satiety and interoceptive stress. van Dijk G; Thiele TE Neuropeptides; 1999 Oct; 33(5):406-14. PubMed ID: 10657518 [TBL] [Abstract][Full Text] [Related]
53. A role for central glucagon-like peptide-1 in temperature regulation. O'Shea D; Gunn I; Chen X; Bloom S; Herbert J Neuroreport; 1996 Feb; 7(3):830-2. PubMed ID: 8733755 [TBL] [Abstract][Full Text] [Related]
54. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556 [TBL] [Abstract][Full Text] [Related]
55. Central infusions of leptin and GLP-1-(7-36) amide differentially stimulate c-FLI in the rat brain. Van Dijk G; Thiele TE; Donahey JC; Campfield LA; Smith FJ; Burn P; Bernstein IL; Woods SC; Seeley RJ Am J Physiol; 1996 Oct; 271(4 Pt 2):R1096-100. PubMed ID: 8898006 [TBL] [Abstract][Full Text] [Related]
56. Ligand-induced regulation of glucagon-like peptide-I receptor function and expression in insulin-secreting beta cells. Fehmann HC; Jiang J; Pitt D; Schweinfurth J; Göke B Pancreas; 1996 Oct; 13(3):273-82. PubMed ID: 8884849 [TBL] [Abstract][Full Text] [Related]
57. Combined stimulation of glucagon-like peptide-1 receptor and inhibition of cannabinoid CB1 receptor act synergistically to reduce food intake and body weight in the rat. Bojanowska E; Radziszewska E J Physiol Pharmacol; 2011 Aug; 62(4):395-402. PubMed ID: 22100840 [TBL] [Abstract][Full Text] [Related]
58. A synthetic glucagon-like peptide-1 analog with improved plasma stability. Ritzel U; Leonhardt U; Ottleben M; Rühmann A; Eckart K; Spiess J; Ramadori G J Endocrinol; 1998 Oct; 159(1):93-102. PubMed ID: 9795346 [TBL] [Abstract][Full Text] [Related]
59. Dexamethasone pretreatment of rat insulinoma cells decreases binding of glucagon-like peptide-1(7-36)amide. Richter G; Göke R; Göke B; Arnold R J Endocrinol; 1990 Sep; 126(3):445-50. PubMed ID: 2170555 [TBL] [Abstract][Full Text] [Related]
60. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Gotthardt M; Fischer M; Naeher I; Holz JB; Jungclas H; Fritsch HW; Béhé M; Göke B; Joseph K; Behr TM Eur J Nucl Med Mol Imaging; 2002 May; 29(5):597-606. PubMed ID: 11976797 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]